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of cure. In contrast to that, if they noticed the symptoms in 
themselves, as much as 5% of medical students and 9% of 
students of other schools would seek medical advice only 
when they made everyday functioning impossible. 
 
Conclusion: The level of HNC cancer knowledge among young 
population is alarmingly low. A large number of students of 
non-medical schools and universities are unaware of its risk 
factors and early symptoms. This group would benefit from 
increasing the number of educational campaigns, which 
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Purpose or Objective: The aim of this study was to evaluate 
the parotid glands toxicity and its relationship with the dose 
in a cohort of head and neck cancer patients treated with 
IMRT. 
 
Material and Methods: 78 patients out of 110 treated in our 
department between January 2011 and October 2015 were 
included in the analysis. Criteria to select patients were: at 
least 6 months follow up, the omo-lateral parotid (OP) close 
to the high (HR) and / or intermediate (IR) risk CTV. 
Characteristics of the studied patients population are shown 
in Table1.The GTV, whenever present, CTV HR (regions at 
high risk of microscopic disease), CTV IR (regions at 
intermediate risk) and CTV LR (regions at low risk) were 
contoured on each slice. The targets were expanded 3 mm to 
obtain the PTVs. The prescribed dose was 66-70 Gy (2 – 2.13 
Gy /fr) to PTV HR, 59.4 – 66 Gy (1.8 – 2 Gy/fr) to PTV IR; 
56.1Gy (1.7 Gy/fr) to PTV LR. IMRT with Simultaneous 
Integrated Boost (SIB) technique was used (41patients were 
treated with Tomotherapy and 36 with VARIAN 21EX). The OP 
and the CP were contoured; PTV SV1 OP and SV2 CP were 
defined as overlapping volumes of PTVs and glands. Priority 
was given to PTV when OP was partially included. The dose 
limit (Dmean) was <= 25 Gy to the whole contralateral gland 
(if not close to GTV N) and < 24 Gy to the volume of CP not 
included in the PTV (external CP). Salivary gland toxicity was 
assessed weekly, during RT, and at 3,6,9,12,18,24 months 




Results: The dose delivered to the PTVs was 67.9 Gy (range 
66-70) 2.02 Gy/fr (1.9 -2.2) to PTV HR, 62.3 Gy (range 58-66) 
1.86 Gy/fr (1.7-2) to PTV IR, 55.9 Gy (range 51-60) 1.68 Gy/fr 
(1.65-2) to PTV LR. The mean dose was 41.56 Gy (range 17.8 
- 66.8) to OP and 24.9 Gy (range 4.7-39.7) to CP; the external 
CP received 21.7 Gy mean dose. 36 (46.1%) patients 
experienced mouth dryness, thickened saliva and altered 
taste (31 G1 and 5 G2) during RT. At a median follow up of 24 
months (range 6-56.2) 19 cases with xerostomia were 
recorded, 15 (19%) G1 and 4 (5,1%) G2. No G3 was observed. 
The symptom was recorded on an average of 8 months (range 
6-15) after RT. Only 13/36 patients with acute salivary 
problems experienced late xerostomia. 
 
Conclusion: In our experience 25 Gy mean dose to the whole 
contra-lateral parotid, with <24 Gy mean dose to the 
external CP, even with sacrifice of the OP, allowed our 
patients to maintain an adequate salivation. 24% of cases 
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Purpose or Objective: Recent studies show that low activity 
(1.1GBq) of RAI is as effective as high activity (3.7GBq) in 
treating those with low-intermediate-risk differentiated 
thyroid cancer (DTC). The purpose of our study was to 
retrospectively review post-operative I131 uptake and 
ablation rates in those with DTC. 
 
Material and Methods: Data was obtained from St. Luke’s 
Radiation Oncology Network (SLRON) patient registry. 
Selection criteria included histologically proven DTC; post-
thyroidectomy; pre and post RAI ablation scan and RAI 
ablation in SLRON. There were 68 cases of DTC treated with 
RAI identified between 2005-2007 that were suitable for 
analysis and met criteria and follow up of ≥5 years 
 
Results: Of the cases analysed 73% were female and 27% 
male with a mean age of 44 years. The predominant 
histological subtype was papillary (73%), followed by 
follicular (22%). Most had early stage disease; Stage I (65%), 
Stage II (22%), Stage III (13%), 39 cases were pN0 and 29 had 
pN1 disease. Regarding surgery performed 39 patients had a 
complete excision CE, 22 had residual disease and there was 
no information for 7 cases. Thirty seven (37) cases had 
microscopically positive margins, 26 were negative and it was 
unknown in 5. Pre RAI ablation, Post op. RAI (I131) uptake in 
these patients was an average of 3.6 % in pN1 disease and 
5.1% in those with pN0 disease. The max uptake was 28%. The 
extent of the surgery tended to influence the trend of 
uptake. There was a trend to a higher mean uptake in those 
who didn’t have a CE with an uptake of 0.1-17%, and mean of 
6.3%. Patients that had a CE had an uptake of 0-28%, and 
mean of 3.9%. In the SLRON there was no standard protocol 
for RAI dosage at the time the patients were treated The 
mean and range of doses of RAI administered was looked at 
based on pre-ablation uptake scans. Group 1 had a pre-
ablation uptake of <4% and group 2 >4%. For group 1 the 
mean dose was 3.9GBq with a range 2.2-7.4GBq, and group 2 
had a mean of 3.7GBq with a range of 2.8-7.4GBq. Post-
ablative RAI131 scans showed an average of 0.07% uptake 
with the majority of patients (33) having <0.1% uptake. At 
the time of analysis 23 patients remained disease free, 10 
had metastases (M1) and 2 had died from metastatic disease.  
 
Conclusion: In those that received RAI ablation, high ablation 
rates ≥90% were shown despite variability in post -op. I131 
uptake and dose of RAI administered. There didn’t appear to 
be an association between those with recurrent or metastatic 
disease and their pre-ablation uptake rates, it was more 
associated with original stage.  
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Purpose or Objective: The aim of this prospective study is 
the comparison of perfusion parameters changes (∆CTPp) 
before and after radio-chemotherapy (RCT) and their 
correlation with maximum standard uptake values variations 
(∆SUV max) among patients (pts) with head and neck tumor 
(HNT), in order to evaluate the prognostic value of perfusion 
CT parameters (CTPp) in predicting response to RCT. 
 
Material and Methods: We enrolled pts with intermediate 
and advanced stage of HNT (stage III-IV), candidated to RCT 
with curative intent. All pts underwent to a pretreatment 
diagnostic and staging workup including perfusion CT (CTP) 
and FDG-PET/CT total body. Pts also perform a CTP 3 weeks 
after the end of RCT (CTP3w) and both CTP and PET/CT 3 
months after the end of RCT (CTP3m and PET/CT 
repectively). We analised variations of following CTPp: Blood 
Flow (BF), Blood Volume (BV), Mean Transit Time (MTT) and 
Permeability-surface product (PS). All RCT treatments were 
performed using intensity modulated radiotherapy technique 
with simultaneous integrated boost. Prescribed doses were 66 
Gy at 2.2 Gy per fraction to high risk volume PTV and 60-54 
Gy at 2.0- 1.8 Gy per fraction respectively to intermediate 
(optional) and low risk PTVs, delivered in 30 daily fractions. 
Concurrent weekly Cisplatin 40 mg/ m2 or Cisplatin 100 
mg/m2 day 1, 22 an 43 was offered to all pts. 
 
Results: From July 2012 to July 2015 25 pts affected by stage 
III/IV HNT candidate to RCT were enrolled in our study. FDG-
PET/CT 3 months after the end of RCT showed a complete 
metabolic response in 16 pts (64%), a partial metabolic 
response in 7 pts (28%), a stable metabolic disease in 1 pts 
and progression metabolic disease in 1 pts (according PERCIS 
criteria). A significant reduction of all CTPp was observed 
from baseline CTP to CTP3w, except for MTT that did not 
show a significant variation (p=0,722). The analysis of 
differences between baseline CTP and CTP3m showed a 
significant reduction of all CTPp (p<0,001), including MTT 
(p=0,001). PET/CT response resulted statistically correlated 
to reduction of all CTPp both at 3 weeks and at 3 months 
after the end of RCT, except for MTT (p=0,998 and 0,692). At 
the multivariate analysis the PS was the only parameter that 
maintain a statistical significance at CTP3m (p=0,037) with a 
significant trend also at CTP3w(p=0,099). 
 
Conclusion: The induced damage on the intratumor 
microvascularization and low resistance flow of neoplastic 
vessels, explain the decrease of BV and BF whereas the 
reduction of neoangiogenesis phenomenon could explain the 
observed decrease of PS.Despite poor sample size, our 
preliminary results seem to be promising for a potential role 
of CTP to predict tumor response. PS seems the most 
valuable to predict the FDG-PET/CT tumor response. Due to 
the small sample size and short follow up, our results need to 
be confirmed in other series. Both funcional and 
morphological datas of the CTP can be usefull in order to 
reduce as much as possible the rate of false positive. 
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Purpose or Objective: The goal of this study is was to 
evaluate the results of treatment of T1N0M0 glottic cancer 
with irradiation, with emphasis on the influence of time from 
diagnosis to the beginning of radiation therapy. 
 
Material and Methods: We performed the retrospective 
analysis of the group of 539 patients with T1N0M0 glottic 
cancer, treated with radiation therapy in one institute 
between 1977 and 2004. In 481 cases (89%) the tumor was 
limited to single vocal cord and in the remaining 58 involved 
both of them. Anterior commisure involvement was observed 
in 173 (32%) of the patients. According to the radiotherapy 
technique and fractionation scheldule, we have divided 
patients into three separate groups: I - two oblique fields, TD 
60 Gy/24 - 277 patients (51%); II - two opposite fields, TD 60 
Gy/30 - 160 (31%); III - one lateral photon-electron beam, TD 
60 Gy/30 - 102 (19%). The average time from laryngeal biopsy 
to the beginning of radiotherapy was 56 days (range: 3 -145 
days).  
 
Results: The 5-year OS and 10-year OS were 84% and 69%, 5- 
and 10-year DFS were 90% and 88%, and the 5- and 10-year LC 
rates were 89% and 87%, respectively. One- dimensional 
analysis revealed following prognostic factors for LC and DFS: 
tobbaco smoking, radiotherapy technique, and the anterior 
commisure involvement. The 5- and 10-year LC rates in the 
group of patients smoking less than 20 cigarettes a day were 
90% and 87%, compared to 76% and 70%, respectively, in the 
group smoking more than 20 cigarettes a day (p=0,01). 
Considering the RT technique, the lowest 5- and 10-year LC 
rates were observed in the group treated with opposite 
beams (80% and 78%, respectively), and the highest when the 
oblique fields were used - 91% and 88%, respectively 
(p=0,002). The tumor involvement of the anterior commisure 
decreased 5-year LC by 15% (92 to 77%), and 10- year LC rate 
by 19% (89 to 70%, respectively, p=0,000). The waiting time 
for the beginning of RT longer than 30 days from the biopsy 
was statistically significant poor prognostic factor for DFS and 
LC. 5- and 10- year LC rates in the group of patients who 
started RT during the period of 30 days from the biopsy were 
92% and 90%, respectively, and in the group which started 
treatment after that time, these LC rates were 84% and 82%, 
respectively (p=0,01).  
 
Conclusion: Radiation therapy is efficient method of 
treatment the T1N0M0 glottic cancer. Prolonged time of 
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Purpose or Objective: To evaluate the overall response rate 
and access the toxicity for patients with locally advanced 
squamous cell carcinoma of head and neck (HNSCC) receiving 
a novative docetaxel-based outpatient neoadjuvant 
chemotherapy regimen. 
 
Material and Methods: The inclusion criteria for this 
prospective study are (1)Age≧20 years old (2) Histologically 
proven squamous cell carcinoma of the oral cavity, 
oropharynx, hypopharynx, or larynx (3)Stage III or stage IVA 
or IVB without distant metastasis, (4) No prior chemotherapy 
given for HNSCC (5) Physician’s intention to treat with 
docetaxel- baed induction therapy (6) Patients’ informed 
consent will be obtained. Tumor response for induction 
chemotherapy will be evaluated in patient with measurable 
disease according to institutional guidance. The induction 
chemotherapy regimen is a novative outpatient regimen. This 
regimen consists of cisplatin 60mg/m2 on day 1, docetaxel 50 
mg/m2 on day 8, 5-Fu 2500 mg/m2 and leucovorin 250 
mg/m2 on day 15, and methotrexate 30 mg/m2 and 
epirubicin 30 mg/m2 on day 21, cycles will be repeated for a 
total 3 to 4 cycles followed by surgery or radiotherapy. 
Responses rate will be reported using Response Evaluation 
Criteria In Solid Tumors (RECIST) criteria in patients with at 
least one measurable lesion. Toxicity will be recoreded using 
the NCI-CTC v.4.03. 
